142 related articles for article (PubMed ID: 9476987)
21. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
Smith FL; Fujimori K; Lowe J; Welch SP
Pharmacol Biochem Behav; 1998 May; 60(1):183-91. PubMed ID: 9610941
[TBL] [Abstract][Full Text] [Related]
22. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
23. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception.
Edsall SA; Knapp RJ; Vanderah TW; Roeske WR; Consroe P; Yamamura HI
Neuroreport; 1996 Jan; 7(2):593-6. PubMed ID: 8730837
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor.
Nalwalk JW; Svokos K; Hough LB
Eur J Pharmacol; 2006 Nov; 549(1-3):79-83. PubMed ID: 16989809
[TBL] [Abstract][Full Text] [Related]
25. The pharmacological activity of inhalation exposure to marijuana smoke in mice.
Lichtman AH; Poklis JL; Poklis A; Wilson DM; Martin BR
Drug Alcohol Depend; 2001 Jul; 63(2):107-16. PubMed ID: 11376914
[TBL] [Abstract][Full Text] [Related]
26. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice.
Welch SP
J Pharmacol Exp Ther; 1993 May; 265(2):633-40. PubMed ID: 8388455
[TBL] [Abstract][Full Text] [Related]
27. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo.
Bilsky EJ; Bernstein RN; Hruby VJ; Rothman RB; Lai J; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):491-501. PubMed ID: 8613959
[TBL] [Abstract][Full Text] [Related]
28. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
29. Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice.
Bass CE; Martin BR
Drug Alcohol Depend; 2000 Aug; 60(2):113-9. PubMed ID: 10940538
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice.
Reche I; Ruiz-Gayo M; Fuentes JA
Neuropharmacology; 1998; 37(2):215-22. PubMed ID: 9680246
[TBL] [Abstract][Full Text] [Related]
31. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Solinas M; Goldberg SR
Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
[TBL] [Abstract][Full Text] [Related]
32. Functional interaction and cross-tolerance between ethanol and Δ9-THC: possible modulation by mouse cerebellar adenosinergic A1/GABAergic-A receptors.
Dar MS
Behav Brain Res; 2014 Aug; 270():287-94. PubMed ID: 24875771
[TBL] [Abstract][Full Text] [Related]
33. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
Pugh G; Mason DJ; Combs V; Welch SP
J Pharmacol Exp Ther; 1997 May; 281(2):730-7. PubMed ID: 9152379
[TBL] [Abstract][Full Text] [Related]
34. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.
Solinas M; Scherma M; Tanda G; Wertheim CE; Fratta W; Goldberg SR
J Pharmacol Exp Ther; 2007 Jun; 321(3):1127-34. PubMed ID: 17351107
[TBL] [Abstract][Full Text] [Related]
35. Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice.
Wiley JL; Smith FL; Razdan RK; Dewey WL
Eur J Pharmacol; 2005 Mar; 510(1-2):59-68. PubMed ID: 15740725
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
[TBL] [Abstract][Full Text] [Related]
37. Blockade of U50,488H analgesia by antisense oligodeoxynucleotides to a kappa-opioid receptor.
Chien CC; Brown G; Pan YX; Pasternak GW
Eur J Pharmacol; 1994 Mar; 253(3):R7-8. PubMed ID: 8200413
[TBL] [Abstract][Full Text] [Related]
38. Sex differences in acute delta-9-tetrahydrocannabinol (Δ
Lulek CF; Maulik M; Mitra S; Guindon J; Morgan DJ; Henderson-Redmond AN
Psychopharmacology (Berl); 2023 Sep; 240(9):1987-2003. PubMed ID: 37516707
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice.
Castañé A; Robledo P; Matifas A; Kieffer BL; Maldonado R
Eur J Neurosci; 2003 Jan; 17(1):155-9. PubMed ID: 12534979
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys.
Wiley JL; Golden KM; Ryan WJ; Balster RL; Razdan RK; Martin BR
Pharmacol Biochem Behav; 1997 Dec; 58(4):1139-43. PubMed ID: 9408225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
